Raqualia Pharma’s Fimecs subsidiary and Astellas Pharma expanded their 2022 joint research collaboration by adding two new targets focused on targeted protein degradation. The agreement extends an ongoing preclinical partnership and signals both companies’ continued investment in degrader modalities. Public disclosures indicate the expansion will accelerate shared discovery efforts and the validation of new degradation-based therapeutic candidates.